Protagonist Therapeutics
PTGX
130 hedge funds and large institutions have $398M invested in Protagonist Therapeutics in 2022 Q3 according to their latest regulatory filings, with 29 funds opening new positions, 40 increasing their positions, 40 reducing their positions, and 29 closing their positions.
717% more call options, than puts
Call options by funds: $7.01M | Put options by funds: $858K
0% more funds holding
Funds holding: 130 → 130 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 29
0% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 40
6% less capital invested
Capital invested by funds: $422M → $398M (-$24.2M)
13.45% less ownership
Funds ownership: 109.63% → 96.17% (-13%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$7.5M |
| 2 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$4.91M |
| 3 |
Morgan Stanley
New York
|
+$4.27M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$3.32M |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$2.41M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$19.9M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$14.4M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
-$8.76M |
| 4 |
Millennium Management
New York
|
-$8.44M |
| 5 |
CAC
Cowen and Company
New York
|
-$8.43M |
PTGX Hedge Fund Activity: Q3 2022 in Review
130 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Protagonist Therapeutics (PTGX) for Q3 2022, worth a combined $398M — down 5.7% from $422M a quarter earlier.
Fund positioning in PTGX was balanced in Q3 2022: 29 funds opened new positions, 29 closed out, 40 added to existing stakes and 40 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $7.5M. The largest seller was State Street, cutting an estimated $19.9M.
- 130 institutional investors held Protagonist Therapeutics (PTGX) as of Q3 2022, unchanged from Q2 2022.
- Funds reported $398M of Protagonist Therapeutics stock for Q3 2022, down 5.7% quarter-over-quarter.
- 29 funds opened new Protagonist Therapeutics positions in Q3 2022 and 29 closed out, a net change of 0 holders.
- The largest Protagonist Therapeutics buyer in Q3 2022 was Citadel Advisors, an estimated $7.5M added.
- The largest Protagonist Therapeutics seller in Q3 2022 was State Street, an estimated $19.9M sold.
Based on aggregated 13F filings for Q3 2022.